Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price objective of $110.00 for the company and are expecting that the company will post $1.54 EPS for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 65 out of 255 based on the ratings given to its competitors.

TARO has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $110.00 target price (up previously from $105.00) on shares of Taro Pharmaceutical Industries in a research note on Tuesday, November 5th. Zacks Investment Research cut shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, November 8th. Finally, ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. raised its holdings in Taro Pharmaceutical Industries by 59.8% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 53,441 shares of the company’s stock worth $4,564,000 after purchasing an additional 20,002 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Taro Pharmaceutical Industries during the 2nd quarter valued at $1,083,000. JPMorgan Chase & Co. lifted its stake in shares of Taro Pharmaceutical Industries by 98.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 22,627 shares of the company’s stock valued at $1,934,000 after buying an additional 11,197 shares in the last quarter. Menta Capital LLC lifted its stake in shares of Taro Pharmaceutical Industries by 122.7% during the 2nd quarter. Menta Capital LLC now owns 15,320 shares of the company’s stock valued at $1,309,000 after buying an additional 8,440 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp boosted its holdings in Taro Pharmaceutical Industries by 1,357.1% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 30,600 shares of the company’s stock worth $2,649,000 after buying an additional 28,500 shares during the period. Hedge funds and other institutional investors own 10.54% of the company’s stock.

Shares of TARO traded down $0.10 during trading on Thursday, reaching $96.05. The company’s stock had a trading volume of 637 shares, compared to its average volume of 118,163. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 13.28 and a beta of 0.52. The company has a fifty day moving average of $82.99 and a two-hundred day moving average of $83.81. Taro Pharmaceutical Industries has a twelve month low of $72.97 and a twelve month high of $109.42.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.26). The company had revenue of $160.85 million for the quarter, compared to analyst estimates of $168.60 million. Taro Pharmaceutical Industries had a return on equity of 14.13% and a net margin of 40.43%. On average, analysts anticipate that Taro Pharmaceutical Industries will post 6.45 earnings per share for the current fiscal year.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

See Also: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Taro Pharmaceutical Industries (TARO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.